share_log

复星医药(02196.HK)：复星健康、宁波复技拟与海南云志共同对复云健康进行增资

Shanghai Fosun Pharmaceutical (02196.HK): Fosun Health, Ningbo Fuji and Hainan Yunzhi jointly increase the capital of Fuyun Health.

Gelonghui Finance ·  Aug 12, 2022 20:55

Gelonghui Shanghai Fosun Pharmaceutical (02196.HK) announcement on August 12thOn August 12, 2022, Fosun Health and Ningbo compound Technology, a subsidiary of the company, signed a capital increase agreement with Hainan Yunzhi and the target company and its shareholders Fosun Hi-Tech, which are related to, among other things, to the target company.Shanghai Fuyun Health Technology Co., Ltd.To increase capital, Fosun Health, Ningbo compound Technology and Hainan Yunzhi plan to contribute 8.5 million yuan, 8.5 million yuan and 3 million yuan respectively in cash to increase the registered capital of the target company.

Prior to this capital increase, the company did not hold any equity interest in the target company. After the completion of this capital increase, the company holds a total of about 56.6666% of the target company through Fosun Health and Ningbo compound Technology, and the target company will become a subsidiary of the company.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment